Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06008730 | Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer | recruiting | Phase 2 | 10 | Emory UniversityOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06497556 | A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer(Krascendo 1) | active not recruiting | Phase 3 | 338 | Hoffmann-La RocheINDUSTRY | 26 | Sep 16, 2026 |
| clinicaltrials |
| NCT07259447 | Efficiency of Contemporary Off-line Adaptive Radiotherapy for Lung Cancer(ECLAIR) | active not recruiting | N/A | 30 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07323732 | A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease | recruiting | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07619339 | A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer | recruiting | Phase 1 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07806773 | Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 80 | Tubulis GmbHINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07822542 | A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | not yet recruiting | Phase 3 | 448 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 16, 2026 | clinicaltrials |
| NCT07822984 | Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy | not yet recruiting | Phase 2 | 374 | Fudan UniversityOTHER | 0 | Sep 16, 2026 | clinicaltrials |
| NCT07823855 | SIB Accelerated Hyperfractionated RT for High-Proliferation NSCLC(HP-SIB-AHFRT) | recruiting | N/A | 15 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | recruiting | Phase 1 / Phase 2 | 300 | PMV Pharmaceuticals, IncINDUSTRY | 9 | Sep 15, 2026 | clinicaltrials |
| NCT04780568 | Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer | recruiting | Phase 1 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04969315 | TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma | recruiting | Phase 1 / Phase 2 | 35 | Portage BiotechINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06033248 | Using Urine Samples to Identify Lung Cancer | recruiting | — | 210 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06899126 | Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer(DESTINY-Lung06) | recruiting | Phase 3 | 686 | Daiichi SankyoINDUSTRY | 23 | Sep 15, 2026 | clinicaltrials |
| NCT07132918 | HEARTS Trial for Thoracic Cancers | recruiting | Phase 2 | 60 | University of Wisconsin, MadisonOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | recruiting | Phase 1 | 160 | EvolveImmune United, IncINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07341737 | SL-28 for Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 60 | Second Life TherapeuticsINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07630168 | Effects of Infusion Timing on Treatment Response in Solid Tumors(TIMED) | recruiting | Phase 2 | 238 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07633613 | Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.(CPI) | not yet recruiting | Phase 4 | 110 | Centre Antoine LacassagneOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 106 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07761910 | Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 10 | Indiana UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819578 | Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC | not yet recruiting | Phase 2 | 30 | Shaodong HongOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT04013542 | Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer | active not recruiting | Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT05059444 | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation(ORACLE) | recruiting | — | 2,285 | Guardant Health, Inc.INDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT05799274 | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors(RAD301) | active not recruiting | Phase 1 | 9 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06303505 | FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC(NAPISTAR1-01) | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 8 | Sep 14, 2026 | clinicaltrials |
| NCT06500455 | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | active not recruiting | Phase 3 | 274 | NRG OncologyOTHER | 4 | Sep 14, 2026 | clinicaltrials |
| NCT07818135 | Comparison of Biportal Versus Multiportal Robotic Approaches for Pulmonary Resection in NSCLC(EC-UMUR) | recruiting | N/A | 80 | Carlos DénizOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07818304 | SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC(Endouble 2) | not yet recruiting | Phase 2 | 61 | The First People's Hospital of LianyungangOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01817192 | Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients) | active not recruiting | N/A | 420 | Razor GenomicsINDUSTRY | 3 | Sep 11, 2026 | clinicaltrials |
| NCT04140500 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 170 | Hoffmann-La RocheINDUSTRY | 9 | Sep 11, 2026 | clinicaltrials |
| NCT04410796 | Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers | recruiting | Phase 2 | 571 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05186974 | Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)(EVOKE-02) | active not recruiting | Phase 2 | 193 | Gilead SciencesINDUSTRY | 12 | Sep 11, 2026 | clinicaltrials |
| NCT05935384 | SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation | recruiting | — | 470 | Guardant Health, Inc.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06083857 | PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06305754 | Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) | active not recruiting | Phase 3 | 550 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Sep 11, 2026 | clinicaltrials |
| NCT06657222 | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT07815873 | Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers(CERBERO) | not yet recruiting | N/A | 360 | European Institute of OncologyOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02259621 | Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC(NA_00092076) | active not recruiting | Phase 2 | 39 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Sep 10, 2026 | clinicaltrials |
| NCT04302025 | A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)(NAUTIKA1) | recruiting | Phase 2 | 99 | Genentech, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04958811 | Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC | active not recruiting | Phase 2 | 29 | Georgetown UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05557045 | A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | active not recruiting | Phase 1 | 98 | Jazz PharmaceuticalsINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06266299 | A Study of KK2269 in Adult Participants With Solid Tumors | recruiting | Phase 1 | 101 | Kyowa Kirin Co., Ltd.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT06269133 | Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants | active not recruiting | — | 1,000 | Regeneron PharmaceuticalsINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06687369 | A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) | active not recruiting | Phase 3 | 726 | mAbxience Research S.L.INDUSTRY | 24 | Sep 10, 2026 | clinicaltrials |
Data updated 14 days agoSource updated Sep 16, 2026source: clinicaltrials